v3.26.3
Business Segment (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Summary of Segment Reporting Information
The table below is a summary of the segment net loss, including significant segment expenses (in millions):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Total revenues9 26 67 214 
Adjusted for expense (income):
Late-stage development programs (1)
54 78 165 207 
Early-stage development and preclinical programs (2)
17 33 56 113 
Compensation and personnel costs59 59 187 187 
Depreciation and amortization2 2 7 7 
Partnership reimbursements(12)(28)(48)(99)
Other segment items (3)
20 24 61 71 
Non-operating income, net(3)(7)(14)(25)
Segment net loss and Consolidated net loss$(128)$(135)$(347)$(247)
(1) R&D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once the related program enters into one or more Phase 3 clinical trials.
(2) R&D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials.
(3) Other segment items include non-allocated program costs and other G&A costs.